Chimerix (CMRX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Chimerix Announces Second Quarter 2015 Financial Results
August 6, 2015 7:30 AM EDTTargeted Enrollment Now Completed for Brincidofovir SUPPRESS and AdVise Trials
Statistically Significant Survival Benefit Demonstrated in Brincidofovir Pivotal Study in Animal Model of Smallpox Infection
DURHAM, N.C., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results and provided a corporate update for the second quarter of 2015.
M. Michelle Berrey, MD, MPH, President and CEO, said, "We are very pleased with the key milestones that we have achieved for... More
